TrueBeam system Novalis

Radio Therapy

Founded in 1972, Israel Scientific Instruments Ltd. is Israel’s foremost supplier of medical radiotherapy equipment, holding ~80% of the local market.

In its capacity as the exclusive representative of Varian Medical Systems in Israel, ISI has supplied Varian medical linear accelerators and related equipment to the following major oncology and radiotherapy institutes:


Read more »

Latest Products & News

  • Brainlab Announces Interoperability of ExacTrac and Varian’s Edge® System

    MUNICH, April 3, 2018 – Today Brainlab announced an agreement with Varian to address interoperability of Brainlab ExacTrac® versions 5.x, 6.x and new product generations currently under development, with Varian’s Clinac® platform, TrueBeam™ and Edge® systems. To support and enhance the interoperability between the companies’ products, Brainlab and Varian will complete joint testing, verification and validation.

  • Varian-Equipped St. Petersburg Proton Therapy Center Completes First Patient Treatment

    PALO ALTO, Calif., March 20, 2018 /PRNewswire/ -- Varian (NYSE: VAR) announced PTC St. Petersburg Center of Nuclear Medicine of the Sergey Berezin Medical Institute successfully completed its first pediatric patient treatment with the Varian ProBeam® proton therapy system. The patient was treated for a brain tumor at Russia's first dedicated proton therapy treatment center. The two-treatment room PTC St. Petersburg Center of Nuclear Medicine of the Sergey Berezin Medical Institute offers image-guided intensity modulated proton therapy (IMPT) with a ProBeam system. Clinicians at the center expect to treat approximately 1,000 patients each year.

  • Varian Acquires Evinance Innovation, Inc.

    Feb. 22, 2018 -- Varian (NYSE: VAR) today announced it has acquired privately-held Montreal-based Evinance Innovation, Inc., a clinical decision support (CDS) software company. This acquisition expands the capabilities of Varian's 360 Oncology™ care management platform by tightly integrating clinical workflow, decision support, and adherence tracking based on leading cancer care guidelines.

  • Varian ARIA, Eclipse and TrueBeam Named Category Leaders in the 2018 Best in KLAS: Software and Services Repo

    Feb. 20, 2018 -- Varian (NYSE: VAR) today announced three of its cancer care solutions have been named Category Leaders in the 2018 Best in KLAS: Software and Services Report by KLAS, an independent research firm specializing in monitoring and reporting on the performance of healthcare vendors. The Category Leaders from Varian are ARIA® oncology information system in Oncology, Eclipse™ treatment planning software in Oncology Treatment Planning, and TrueBeam™ treatment system in Radiation Therapy.

  • Mobius Medical Systems

    Feb. 5, 2018 - Varian (NYSE: VAR) today announced it has acquired privately-held Mobius Medical Systems®, a leader in radiation oncology Quality Assurance (QA) software.

  • Sirtex

    Varian (NYSE: VAR) announced that it will discuss the details of the M&A agreement, to acquire all the outstanding shares of Sirtex Medical Limited (ASX: SRX) ("Sirtex"). Sirtex is an Australia-based global life sciences company focused on interventional oncology therapies, that is listed on the Australian Securities Exchange.


    The Halcyon™ system is Varian’s newest cancer treatment device, engineered to simplify and enhance virtually every aspect of image-guided volumetric intensity-modulated radiotherapy (IMRT). Halcyon combines fast volumetric imaging and dose delivery with the power of Eclipse™ treatment planning system in a transformative platform.

  • TrueBeam Radiotherapy System

    TrueBeam system brings leading edge cancer care to communities by positioning clinics at the forefront in the fight against cancer. Designed from the ground up to treat moving targets with advanced speed and accuracy, the TrueBeam platform is a fully-integrated system for image-guided radiotherapy and radiosurgery.

  • VARIAN TrueBeam System With SkyLigth

  • Novalis

    Novalis Radiosurgery strengthens the strategic position of facilities dedicated to a comprehensive and focused vision for excellence in targeted cancer treatments.

Jump to page content